SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GZMO
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: D. Chapman who wrote (78)9/14/1999 10:07:00 AM
From: jeffbas  Read Replies (2) of 438
 
Please explain then, since I am not a scientist. They have been doing melanoma trials for a long time using the same technology. Do you really think they would have started on another cancer if they were getting poor results?

Furthermore, using AIDS as an analogy of a mutating disease, it seems that the cocktail approach has cut the death rate there dramatically, even if not effecting a cure. I doubt afflicted patients would agree
that a temporarily effective treatment has no value. Again as a non-scientist, I think it would depend on how short "temporary" is and
how quality of life is affected by the treatment itself.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News